Citations

Mayo Clinic

Clear

541 citation(s) found for "Bailey, Baños".

HYDRATION FOLDS IN RHEGMATOGENOUS RETINAL DETACHMENT
Spaide, Richard F. , Yannuzzi, Lawrence A. , Freund, K. Bailey , Pulido, José S. , Dalvin, Lauren A.

RETINAL Cases & Brief Reports | February 21, 2018 | Volume: 14 | Issue: 4 | Pages: 355-359

10.1097/icb.0000000000000711 | PMID 29470302 Get It

Purpose: To describe two cases of retinal detachment with hydration folds and discuss the possible cause of these outer retinal abnormalities. Methods: The medical and imaging records of two patients with retinal detachment and hydration folds were examined. Patients: A 43-year-old myopic woman who developed a retinal detachment secondary to a macular hole and a 35-year-old man referred with a rhegmatogenous retinal detachment masquerading as an exudative detachment were each found to have retinal hydration folds. Results: On near-infrared reflectance imaging, the hydration folds appeared similar to eddy currents, and these corresponded to curvilinear outer retinal plications on optical coherence tomography. The photoreceptor outer segments appeared thickened and elongated, and there was apparent lateral expansion of the outer retinal layers. Conclusion: Hydration folds are found in rhegmatogenous retinal detachment and demonstrate reproducible imaging characteristics on near-infrared imaging and optical coherence tomography. The cause for such outer retinal plications is currently unknown. We suspect that they form as a result of hydration of the glycosaminoglycans in the interphotoreceptor matrix, which lies between the photoreceptors. Additional studies are warranted to explore this pathophysiology.
Preoperative Ultrasonography Is Unreliable in Predicting Hamstring Tendon Graft Diameter for ACL Reconstruction
Momaya, Amit , Beicker, Clint, Siffri, Paul, Kissenberth, Michael J. , Backes, Jeffrey, Bailey, Lane , Rulewicz, Gabriel J., Mercuri, Jennifer M., Shealy, E. Carlisle, Tokish, John M. , Thigpen, Charles A.

Orthopaedic Journal of Sports Medicine | January 4, 2018 | Volume: 6 | Issue: 1 | Pages: No page available

10.1177/2325967117746146 | PMID 29318179 Get It

Background: Hamstring autograft size <8 mm has been shown to be a predictor for failure after anterior cruciate ligament (ACL) reconstruction. The ability to predict graft size preoperatively is helpful in counseling patients about the possible need for graft augmentation. Purpose: To determine whether preoperative ultrasound (US) measurements of hamstring tendons can predict intraoperative graft diameter during ACL reconstruction. Study Design: Cohort study (diagnosis); Level of evidence, 2. Methods: Twenty patients undergoing unilateral isolated ACL reconstruction were prospectively enrolled in the study (10 males, 10 females; mean ± SD age, 22.8 ± 6.6 years; height, 175.1 ± 7.1 cm; weight, 81.4 ± 14.2 kg; body mass index, 26.5 ± 4.1 kg/m 2 ). Hamstrings were assessed by US, and double-looped semitendinosus-gracilis hamstring size was independently calculated with a freehand selection method on a nonmagnified US image by 2 orthopaedic surgeons. Intraoperative autograft size was determined with a standard graft-sizing tool. Intra- and interrater reliability was measured with intraclass correlation coefficients (ICCs) and standard error of the measure (SEM). A receiver operating characteristic curve was calculated to assess the ability of the US measurement to predict intraoperative measurements. Results: The mean autograft diameter by US was 8.9 ± 0.98 mm, while the mean intraoperative hamstring graft size was 8.1 ± 0.89 mm. There was excellent intrarater (ICC 2,1 = 0.95, SEM = 0.32 mm) and interrater (ICC 2,1 = 0.88, SEM = 0.55 mm) reliability for US measurements. Receiver operating characteristic analysis showed that US did not consistently quantify graft size. Graft size did not significantly correlate with height, weight, or body mass index in our sample ( P > .05). Conclusion: These results suggest that preoperative US imaging of the hamstring tendons is unreliable in predicting intraoperative graft diameter.
Validation of two-pool model for in vivo ketone body kinetics
Haymond, Morey W. , Bailey, James , Miles, John J.

American Journal of Physiology-Endocrinology and Metabolism | December 22, 2017 | Volume: 258 | Issue: 5 | Pages: E850-E855

10.1152/ajpendo.1990.258.5.e850 | PMID 2185666 Get It

Previous studies have indicated that simultaneous infusions of two ketone body tracers ([13C]acetoacetate and [14C]beta-hydroxybutyrate) provide accurate estimates of exogenous ketone body inflow when an open two-pool model is employed. In the present studies, net hepatic ketone body production was determined from surgically placed arterial, portal venous, and hepatic venous catheters in conscious diabetic (n = 6) and 4-day fasted (n = 7) dogs. [13C]acetoacetate and [14C]beta-hydroxybutyrate were infused simultaneously, and ketone body production was calculated from either acetoacetate (AcAc) single-isotope data, beta-hydroxybutyrate (beta-OHB) single-isotope data, the sum of individual fluxes, or the two-pool model. In fasted animals, both the AcAc single-isotope calculation and the sum of individual fluxes overestimated net hepatic production by approximately 50% (P less than 0.05), whereas the beta-OHB single-isotope calculation and the two-pool model gave accurate estimates. In the diabetic animals, the beta-OHB single-isotope calculation underestimated net hepatic production by approximately 30% (P less than 0.05). The sum of individual fluxes overestimated net hepatic production by approximately 46% (P less than 0.05), whereas both the AcAc single-isotope calculation and the two-pool model gave accurate estimates. In conclusion, single-isotope methods give erroneous estimates of net hepatic production of ketone bodies. In contrast, a two-pool model provided an accurate estimate of net hepatic production and thus appears to be suitable for determination of ketone body kinetics in humans.
A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure
Kawakami, Rika , Lee, Candace Y.W., Bailey, Kent R. , Schirger, John A., Chen, Horng H. , Benike, Sherry L., Cannone, Valentina , Martín, Fernando L., Sangaralingham, S. Jeson , Ichiki, Tomoko , Burnett, John C. , Kawakami, Rika , Scott, Christopher G. , Sangaralingham, S. Jeson , Kawakami, Rika

Clinical Pharmacology & Therapeutics | December 11, 2017 | Volume: 104 | Issue: 3 | Pages: 546-552

10.1002/cpt.974 | PMID 29226471 Get It

Cenderitide is a novel designer natriuretic peptide (NP) composed of C‐type natriuretic peptide (CNP) fused to the C‐terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to coactivate the two NP receptors, particulate guanylyl cyclase (pGC)‐A and ‐B. The rationale for its design was to achieve the renal‐enhancing and antifibrotic properties of dual receptor activation, but without clinically significant hypotension. Here we report the first clinical trial on the safety, tolerability, and cyclic guanosine monophosphate (cGMP) activating properties of Cenderitide in subjects with stable heart failure (HF). Four‐hour infusion of Cenderitide was safe, well‐tolerated, and significantly increased plasma cGMP levels and urinary cGMP excretion without adverse effects with no change in blood pressure. Thus, Cenderitide has a favorable safety profile and expected pharmacological effects in stable human HF. Our results support further investigations of Cenderitide in HF as a potential future cGMP‐enhancing therapeutic strategy.
Pregnancy history, coronary artery calcification and bone mineral density in menopausal women
Beckman, John , Camp, Jon J. , Lahr, Brian D. , Bailey, Kent R. , Kearns, Ann E. , Jayachandran, Muthuvel , Miller, Virginia M. , Holmes, David R. , Garovic, Vesna D.

Climacteric | November 30, 2017 | Volume: 21 | Issue: 1 | Pages: 53-59

10.1080/13697137.2017.1406910 | PMID 29189095 Get It

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Norquist, Barbara M. , Brady, Mark F. , Harrell, Maria I., Lee, Ming K. , Bernards, Sarah S., Casadei, Silvia , Burger, Robert A. , Tewari, Krishnansu S. , Mannel, Robert S., Bailey, Cheryl L., Rubin, Stephen C. , Soper, John T. , Lankes, Heather A. , Ramirez, Nilsa C. , King, Mary‐Claire , Birrer, Michael J. , Swisher, Elizabeth M. , Glaser, Gretchen , Swisher, Elizabeth M , Walsh, Tom D. , Gülsüner, Süleyman , Backes, Floor , Norquist, Barbara

Clinical Cancer Research | November 30, 2017 | Volume: 24 | Issue: 4 | Pages: 777-783

10.1158/1078-0432.ccr-17-1327 | PMID 29191972 Get It

Abstract Purpose: We hypothesized that mutations in homologous recombination repair (HRR) genes beyond BRCA1 and BRCA2 improve outcomes for ovarian carcinoma patients treated with platinum therapy and would impact the relative benefit of adding prolonged bevacizumab. Experimental Design: We sequenced DNA from blood and/or neoplasm from 1,195 women enrolled in GOG-0218, a randomized phase III trial in advanced ovarian carcinoma of bevacizumab added to carboplatin and paclitaxel. Defects in HRR were defined as damaging mutations in 16 genes. Proportional hazards models were used to estimate relative hazards for progression-free survival (PFS) and overall survival (OS). Results: Of 1,195 women with ovarian carcinoma, HRR mutations were identified in 307 (25.7%). Adjusted hazards for progression and death compared with those without mutations were lower for women with non-BRCA HRR mutations [HR = 0.73; 95% confidence interval (CI), 0.57–0.94; P = 0.01 for PFS; HR = 0.67; 95% CI, 0.50–0.90; P = 0.007 for OS] and BRCA1 mutations (HR = 0.80; 95% CI, 0.66–0.97; P = 0.02 for PFS; HR = 0.74; 95% CI, 0.59–0.94; P = 0.01 for OS) and were lowest for BRCA2 mutations (HR = 0.52; 95% CI, 0.40–0.67; P &lt; 0.0001 for PFS; HR = 0.36; 95% CI, 0.25–0.53; P &lt; 0.0001 for OS). A test of interaction showed no difference in the effect of bevacizumab on PFS between cases with and without mutations. Conclusions: HRR mutations, including non-BRCA genes, significantly prolong PFS and OS in ovarian carcinoma and should be stratified for in clinical trials. The benefit of adding bevacizumab was not significantly modified by mutation status. Clin Cancer Res; 24(4); 777–83. ©2017 AACR.
Objective Versus Self-Reported Sleep Quality at High Altitude
Anderson, Paul J., Wood‐Wentz, Christina M. , Bailey, Kent R., Johnson, Bruce D.

High Altitude Medicine & Biology | November 27, 2017 | Volume: 24 | Issue: 2 | Pages: 144-148

10.1089/ham.2017.0078 | PMID 29172727 Get It

Anderson, Paul J., Christina M. Wood-Wentz, Kent R. Bailey, and Bruce D. Johnson. Objective versus self-reported sleep quality at high altitude. High Alt Med Biol . 24:144–148, 2023. Background: Previous studies have found little relationship between polysomnography and a diagnosis of acute mountain sickness (AMS) using the Lake Louise Symptom Questionnaire (LLSQ). The correlation between sleep question responses on the LLSQ and polysomnography results has not been explored. We compared LLSQ sleep responses and polysomnography data from our previous study of workers rapidly transported to the South Pole. Methods: Sixty-three subjects completed a 3-hour flight from sea level to the South Pole (3200 m, 9800 ft). Participants completed limited overnight polysomnography on their first night and completed LLSQ upon awakening. We compared polysomnography results at the South Pole with sleep question responses on the LLSQ to assess their degree of correspondence. Results: Twenty-two (30%) individuals reported no sleep problems whereas 20 (32%) reported some problems and 20 (33%) individuals reported poor sleep and 1 reported no sleep ( n = 1). Median sleep efficiency was (94%) among response groups and mean overnight oxygen saturation was 81%. Median apnea hypopnea index (AHI; events/hour) was 10.2 in those who reported no problems sleeping, 5.1 in those reporting some problems sleeping, and 13.7 in those who reported poor sleep. These differences were not statistically significant. Conclusion: Self-reported sleep quality varied but there were no associated significant differences in sleep efficiency, overnight oxygen saturation, nor AHI. Studies that explore the role of objective sleep quality in the development of AMS should remove the sleep question on the LLSQ from AMS scoring algorithms.
17α‐estradiol acts through hypothalamic pro‐opiomelanocortin expressing neurons to reduce feeding behavior
Steyn, Frederik J. , Ngo, Shyuan T. , Chen, Vicky Ping , Bailey‐Downs, Lora C., Xie, Teresa, Ghadami, Martin, Brimijoin, Stephen , Freeman, Willard M. , Rubinstein, Marcelo , Low, Malcolm J. , Steyn, F J , Freeman, Willard M , Stout, Michael B

Aging Cell | November 23, 2017 | Volume: 17 | Issue: 1 | Pages: No page available

10.1111/acel.12703 | PMID 29168299 Get It

SummaryWeight loss is an effective intervention for diminishing disease burden in obese older adults. Pharmacological interventions that reduce food intake and thereby promote weight loss may offer effective strategies to reduce age‐related disease. We previously reported that 17α‐estradiol (17α‐E2) administration elicits beneficial effects on metabolism and inflammation in old male mice. These observations were associated with reduced calorie intake. Here, we demonstrate that 17α‐E2 acts through pro‐opiomelanocortin (Pomc) expression in the arcuate nucleus (ARC) to reduce food intake and body mass in mouse models of obesity. These results confirm that 17α‐E2 modulates appetite through selective interactions within hypothalamic anorexigenic pathways. Interestingly, some peripheral markers of metabolic homeostasis were also improved in animals with near complete loss of ARC Pomc transcription. This suggests that 17α‐E2 might have central and peripheral actions that can beneficially affect metabolism cooperatively or independently.
Cerebrovascular Reactivity and Vascular Activation in Postmenopausal Women With Histories of Preeclampsia
Barnes, Jill N. , Harvey, Ronée E. , Miller, Kathleen B. , Jayachandran, Muthuvel , Malterer, Katherine R., Lahr, Brian D. , Bailey, Kent R. , Joyner, Michael J. , Miller, Virginia M. , Barnes, J N , Harvey, Ronée E , Joyner, Michael J

Hypertension | November 20, 2017 | Volume: 71 | Issue: 1 | Pages: 110-117

10.1161/hypertensionaha.117.10248 | PMID 29158356 Get It

Cerebrovascular reactivity (CVR) is reduced in patients with cognitive decline. Women with a history of preeclampsia are at increased risk for cognitive decline. This study examined an association between pregnancy history and CVR using a subgroup of 40 age- and parity-matched pairs of women having histories of preeclampsia (n=27) or normotensive pregnancy (n=29) and the association of activated blood elements with CVR. Middle cerebral artery velocity was measured by Doppler ultrasound before and during hypercapnia to assess CVR. Thirty-eight parameters of blood cellular elements, microvesicles, and cell–cell interactions measured in venous blood were assessed for association with CVR using principal component analysis. Middle cerebral artery velocity was lower in the preeclampsia compared with the normotensive group at baseline (63±4 versus 73±3 cm/s; P =0.047) and during hypercapnia ( P =0.013–0.056). CVR was significantly lower in the preeclampsia compared with the normotensive group (2.1±1.3 versus 2.9±1.1 cm·s·mm Hg; P =0.009). Globally, the association of the 7 identified principal components with preeclampsia ( P =0.107) and with baseline middle cerebral artery velocity ( P =0.067) did not reach statistical significance. The interaction between pregnancy history and principal components with respect to CVR ( P =0.084) was driven by a nominally significant interaction between preeclampsia and the individual principal component defined by blood elements, platelet aggregation, and interactions of platelets with monocytes and granulocytes ( P =0.008). These results suggest that having a history of preeclampsia negatively affects the cerebral circulation years beyond the pregnancy and that this effect was associated with activated blood elements.